Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Last trade$142.20
Day change-$2.405 (-1.66%)
Day range$140.77 – $147.57
Volume129,184
Market cap$2.11B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.11B
Price / earnings
—
Price / book
10.68×
Price / sales
—
EV / sales
—
EV / EBITDA
-27.32×
Profitability
Earnings per share
-$5.13
Return on assets
-31.33%
Return on equity
-37.89%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
16.01×
Quick ratio
16.01×
Cash ratio
12.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.06M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PVLA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$11.9M
$8.93M
$5.52M
$4.18M
$3.65M
$4.13M
$3.8M
$1.82M
Research and development
$10.82M
$12.47M
$9.33M
$7.12M
$6.53M
$5.12M
$4.07M
$2.54M
Total operating expenses
$22.73M
$21.41M
$14.86M
$11.3M
$10.18M
$9.25M
$7.87M
$4.37M
Operating income
-$22.73M
-$21.41M
-$14.86M
-$11.3M
-$10.18M
-$9.25M
-$7.87M
-$4.37M
Interest expense
-$2.81M
-$2.31M
-$2.04M
-$1.74M
-$1.51M
-$1.35M
-$1.22M
-$1.3M
Income before taxes
-$24.64M
-$21.87M
-$15.77M
-$12.71M
-$11.35M
-$9.47M
-$8.19M
-$3.95M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$24.64M
-$21.87M
-$15.77M
-$12.71M
-$11.35M
-$9.47M
-$8.19M
-$3.95M
Net income attributable to common shareholders
-$24.64M
-$21.87M
-$15.77M
-$12.71M
-$11.35M
-$9.47M
-$8.19M
-$3.37M
EBITDA
-$22.73M
-$21.41M
-$14.86M
-$11.3M
-$10.18M
-$9.25M
-$7.87M
-$4.37M
Basic earnings per share
-$1.70
-$1.52
-$1.20
-$1.07
-$1.03
-$0.86
-$0.74
-$0.94
Diluted earnings per share
-$1.70
-$1.52
-$1.20
-$1.07
-$1.03
-$0.86
-$0.74
-$0.94
Recent news
Company coverage with links to the original publishers.
Palvella Therapeutics' Chief Operating Officer Kathleen Goin sold 4,302 shares worth $476,000 through a pre-planned trading arrangement, while retaining 17,219 options. The sale comes amid a 620% one-year stock surge driven by investor optimism about the company's QTORIN rapamycin therapy for rare skin diseases. The FDA recently granted rolling review for the drug's New Drug Application, with the company targeting NDA completion in H2 2026.
Palvella Therapeutics' COO Kathleen Goin sold 4,302 shares worth ~$508,000 on March 18, 2026, through a pre-planned Rule 10b5-1 trading plan adopted in August. The sale should not raise concerns as it was a structured liquidity event tied to option exercises. The stock has surged 340% over the past year, supported by positive Phase 3 results for its lead candidate QTORIN rapamycin (95% of participants showed improvement), a planned New Drug Application submission in H2 2026, and a recent $230 million equity offering.
Palvella Therapeutics (NASDAQ: PVLA) closed its upsized public offering on February 27, 2026, raising $230.0 million in gross proceeds by selling 1,840,000 shares at $125.00 per share, including the full exercise of underwriters' option for 240,000 additional shares. The company plans to use the net proceeds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations.
Palvella Therapeutics priced an upsized public offering of 1.6 million shares at $125 per share, raising $200 million in gross proceeds before underwriting costs. The clinical-stage biopharmaceutical company plans to use the funds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations. The offering is expected to close on February 27, 2026.
Palvella Therapeutics announced it will host a conference call on February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations. The company plans to release results at 6:30am ET prior to the call.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.